Abstract
The present study investigated potential anti-cataleptic properties of the prototype atypical antipsychotic clozapine and two newly developed atypical antipsychotics, olanzapine and quetiapine, which are structurally related and display similar pharmacological profiles to clozapine. Clozapine (2.5 mg kg-1, s.c.), but not olanzapine (2.0 mg kg-1, s.c.) and quetiapine (20.0 mg kg-1, s.c.), blocked catalepsy induced either by the dopamine D1/5 receptor antagonist SCH 23390 (50.0 μg kg-1, s.c) or the selective dopamine D2/3 receptor antagonist raclopride (4.0 mg kg-1, s.c.). Such findings are consistent with the beneficial effects of clozapine in the management of drug-induced psychosis in parkinsonian patients, and suggest that neither olanzapine nor quetiapine may be a safe alternative to clozapine in this field. Furthermore, the results indicate that clozapine has a unique pharmacological profile that distinguishes it from olanzapine and quetiapine. The mechanisms underlying anti-cataleptic or anti-parkinsonian properties of clozapine are unclear but may be related to dopamine D1 receptor agonism of clozapine.
| Original language | English |
|---|---|
| Pages (from-to) | 177-182 |
| Number of pages | 6 |
| Journal | European Neuropsychopharmacology |
| Volume | 13 |
| Issue number | 3 |
| DOIs | |
| State | Published - May 1 2003 |
| Externally published | Yes |
Fingerprint
Keywords
- Atypical antipsychotics
- Catalepsy
- Clozapine
- Olanzapine
- Parkinson's disease
- Quetiapine
ASJC Scopus subject areas
- Clinical Neurology
- Psychiatry and Mental health
- Biological Psychiatry
- Neurology
- Pharmacology
- Psychology(all)
Cite this
Anti-cataleptic effects of clozapine, but not olanzapine and quetiapine, on SCH 23390- or raclopride-induced catalepsy in rats. / Ahlqvist, Jenny; Isacson, Ruben; Wahlestedt, Claes R; Salmi, Peter.
In: European Neuropsychopharmacology, Vol. 13, No. 3, 01.05.2003, p. 177-182.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Anti-cataleptic effects of clozapine, but not olanzapine and quetiapine, on SCH 23390- or raclopride-induced catalepsy in rats
AU - Ahlqvist, Jenny
AU - Isacson, Ruben
AU - Wahlestedt, Claes R
AU - Salmi, Peter
PY - 2003/5/1
Y1 - 2003/5/1
N2 - The present study investigated potential anti-cataleptic properties of the prototype atypical antipsychotic clozapine and two newly developed atypical antipsychotics, olanzapine and quetiapine, which are structurally related and display similar pharmacological profiles to clozapine. Clozapine (2.5 mg kg-1, s.c.), but not olanzapine (2.0 mg kg-1, s.c.) and quetiapine (20.0 mg kg-1, s.c.), blocked catalepsy induced either by the dopamine D1/5 receptor antagonist SCH 23390 (50.0 μg kg-1, s.c) or the selective dopamine D2/3 receptor antagonist raclopride (4.0 mg kg-1, s.c.). Such findings are consistent with the beneficial effects of clozapine in the management of drug-induced psychosis in parkinsonian patients, and suggest that neither olanzapine nor quetiapine may be a safe alternative to clozapine in this field. Furthermore, the results indicate that clozapine has a unique pharmacological profile that distinguishes it from olanzapine and quetiapine. The mechanisms underlying anti-cataleptic or anti-parkinsonian properties of clozapine are unclear but may be related to dopamine D1 receptor agonism of clozapine.
AB - The present study investigated potential anti-cataleptic properties of the prototype atypical antipsychotic clozapine and two newly developed atypical antipsychotics, olanzapine and quetiapine, which are structurally related and display similar pharmacological profiles to clozapine. Clozapine (2.5 mg kg-1, s.c.), but not olanzapine (2.0 mg kg-1, s.c.) and quetiapine (20.0 mg kg-1, s.c.), blocked catalepsy induced either by the dopamine D1/5 receptor antagonist SCH 23390 (50.0 μg kg-1, s.c) or the selective dopamine D2/3 receptor antagonist raclopride (4.0 mg kg-1, s.c.). Such findings are consistent with the beneficial effects of clozapine in the management of drug-induced psychosis in parkinsonian patients, and suggest that neither olanzapine nor quetiapine may be a safe alternative to clozapine in this field. Furthermore, the results indicate that clozapine has a unique pharmacological profile that distinguishes it from olanzapine and quetiapine. The mechanisms underlying anti-cataleptic or anti-parkinsonian properties of clozapine are unclear but may be related to dopamine D1 receptor agonism of clozapine.
KW - Atypical antipsychotics
KW - Catalepsy
KW - Clozapine
KW - Olanzapine
KW - Parkinson's disease
KW - Quetiapine
UR - http://www.scopus.com/inward/record.url?scp=0037406047&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037406047&partnerID=8YFLogxK
U2 - 10.1016/S0924-977X(03)00004-X
DO - 10.1016/S0924-977X(03)00004-X
M3 - Article
VL - 13
SP - 177
EP - 182
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
SN - 0924-977X
IS - 3
ER -